Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCAT | P04180 | 20/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16648496 | 0.87 | LCAT (0.73) | LCAT | |
| SCHEMBL16648495 | 0.86 | LCAT (0.73) | LCAT | |
| SCHEMBL16648877 | 0.84 | LCAT (0.73) | LCAT | |
| SCHEMBL16648824 | 0.83 | LCAT (0.75) | LCAT | |
| SCHEMBL16648985 | 0.80 | LCAT (0.73) | LCAT | |
| SCHEMBL16648841 | 0.80 | LCAT (0.73) | LCAT | |
| SCHEMBL16648715 | 0.80 | LCAT (0.73) | LCAT | |
| SCHEMBL16648673 | 0.79 | LCAT (0.72) | LCAT | |
| SCHEMBL16648763 | 0.79 | LCAT (0.55) | LCAT | |
| SCHEMBL16649001 | 0.79 | LCAT (0.71) | LCAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2862861-B1 | PIPERIDINYLPYRAZOLOPYRIDINE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2016-01-06 | — | — | EP | disclosed |
| US-9150575-B2 | Piperidinylpyrazolopyridine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-10-06 | — | — | US | disclosed |
| US-20150152102-A1 | PIPERIDINYLPYRAZOLOPYRIDINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-06-04 | — | — | US | disclosed |
| EP-2862861-A1 | PIPERIDINYLPYRAZOLOPYRIDINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152102-A1 | PIPERIDINYLPYRAZOLOPYRIDINE DERIVATIVE | LCAT, LPL, LCLAT1 | LCAT 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.